1. 191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. (December 2022) Authors: Jimeno, A.; Miselis, N.R.; Park, J.C.; Jennings, J.; Dhani, N.; Holtick, U.; Iams, W.T.; Rodabaugh, K.; Nair, N.; Kornacker, M.; Loughhead, S.M.; Bernstein, H.; Zwirtes, R.; Ji, R.R.; Warren, M.; Sharei, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Genomic and transcriptomic characterization of advanced pancreatic ductal adenocarcinoma (PDAC) may inform systemic therapy. (April 2017) Authors: Connor, A.; Fischer, S.; Aung, K.; Denroche, R.; Jang, G.; Notta, F.; Ghai, S.; Wilson, J.; Liang, S.; Chadwick, D.; Dhani, N.; Hedley, D.; Knox, J.; Gallinger, S. Journal: HPB Issue: Volume 19(2017)Supplement 1 Page Start: S9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗